Comparative Pharmacology
Head-to-head clinical analysis: GLUCOTROL XL versus GLYNASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOTROL XL versus GLYNASE.
GLUCOTROL XL vs GLYNASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin secretion from pancreatic beta cells by binding to ATP-sensitive potassium channels, causing depolarization and calcium influx, leading to insulin release.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Initial dose: 5 mg orally once daily with breakfast. Titrate by 2.5-5 mg increments at weekly intervals based on glycemic response. Maximum dose: 20 mg once daily.
Initial dose 2.5-5 mg orally once daily with breakfast. Titrate by 2.5-5 mg weekly. Maximum dose 20 mg daily. Divided doses twice daily may be used for doses >10 mg.
None Documented
None Documented
Terminal elimination half-life 2-5 hours; however, due to extended-release formulation, therapeutic effects persist up to 24 hours.
Terminal elimination half-life: 10-16 hours; clinical context: correlates with duration of glucose-lowering effect, prolonged in renal impairment.
Renal: ~70% as metabolites (primarily hydroxylated and conjugated metabolites), unchanged drug <10%; Fecal: ~20% via bile.
Renal: approximately 50% as metabolites and unchanged drug; fecal/biliary: minor (less than 5% as unchanged drug).
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic